BRD4 and renal cell carcinoma: However, the efficacy of BET inhibitors in renal cell carcinoma (RCC) was poorly evaluated, and it remained to be answered whether BRD4, as well as other BET family members, can serve as therapeutic targets for the treatment of RCC.